祛痰化瘀颗粒治疗中风（中经络）恢复期风痰瘀阻证临床观察

发布时间：2018-06-26 14:14

本文选题：中风中经络恢复期 + 风痰瘀阻证　；参考：《辽宁中医药大学》2017年硕士论文

【摘要】：目的:通过对祛痰化瘀颗粒治疗中风(中经络)恢复期风痰瘀阻证的研究,观察祛痰化瘀颗粒的临床疗效和安全性。材料与方法:所选研究对象系2016年9月-2017年3月在辽宁中医药大学附属第二医院、普兰店中医院、锦州市中医院、东港市中医院经门诊和病房就诊的32例中风(中经络)恢复期风痰瘀阻证患者。用随机数字表法,按1:1的比例,分为祛痰化瘀颗粒试验组和阿司匹林对照组,每组16例,按照受试者的入组的先后顺序以及从小到大的药物编码顺序逐例发药。祛痰化瘀颗粒试验组,1袋,日三次口服,用药4周;阿司匹林对照组,100mg,日一次口服,用药4周。在用药前-3-0天和用药后28±3天各做一次实验检查,以血常规、尿常规、便常规、心电图、肝功能、肾功能、血流变、不良反应及不良事件作为安全性指标,来评定祛痰化瘀颗粒的安全性。在用药前-3-0天及用药后28±3天各观察记录一次NIHSS评分和中医证候评分,并做统计学处理,来评定祛痰化瘀颗粒的临床疗效。结果:1.两组间均衡比较:两组患者在性别、年龄分布方面无明显差异(P0.05),说明两组间有可比性;两组治疗前NIHSS评分积分组间比较,无明显差异(P0.05),说明两组间有可比性;两组治疗前中医证候评分积分组间比较,无明显差异(P0.05),说明两组间有可比性。2.治疗结果:两组治疗后NIHSS评分积分与自身治疗前比较,有显著差异(P0.05),说明治疗后两组NIHSS评分积分较治疗前均降低;试验组治疗后与对照组治疗后NIHSS评分疗效组间比较,有显著差异(P0.05),说明在总体疗效上,试验组优于对照组。两组治疗后中医证候评分积分与自身治疗前比较,有显著差异(P0.05),说明治疗后两组中医证候评分积分较治疗前均降低;试验组治疗后与对照组治疗后中医证候评分疗效组间比较,有显著差异(P0.05),说明在总体疗效上,试验组优于对照组。3.安全性检测:经安全性检测,观察患者血常规、尿常规、便常规、心电图、肝功能、肾功能、血流变、用药期间有无不良事件和不良反应,显示在用祛痰化瘀颗粒治疗期间未出现不良反应,没有因为严重不良事件而中断治疗的。结论:祛痰化瘀颗粒可以改善中风(中经络)恢复期风痰瘀阻证患者的临床症状,祛痰化瘀颗粒疗效可靠,在用祛痰化瘀颗粒治疗期间无不良反应及不良事件。
[Abstract]:Objective: to observe the clinical efficacy and safety of Quphan Huayu granule in treating the syndrome of wind and phlegm stasis in convalescent period of apoplexy (middle meridian). Materials and methods: the subjects were selected from September 2016 to March 2017 in the second affiliated Hospital of Liaoning University of traditional Chinese Medicine, Plandian Chinese Medicine Hospital, Jinzhou traditional Chinese Medicine Hospital. Thirty-two patients with wind and phlegm stasis syndrome in convalescent stage of stroke in Donggang traditional Chinese Medicine Hospital. By means of random digital table method, according to the proportion of 1:1, the experimental group of removing phlegm and removing blood stasis granule and the control group of aspirin were divided into two groups, 16 cases in each group. According to the order of entering the group and the order of drug coding from small to large, the patients were given drugs one by one. The test group was treated with 1 bag three times a day for 4 weeks, while the aspirin control group took 100 mg once a day for 4 weeks. Before and 28 卤3 days after medication, an experimental examination was performed. Routine blood, urine routine, routine stool, electrocardiogram, liver function, renal function, hemorheology, adverse reactions and adverse events were used as safety indicators. To assess the safety of expectorant and blood stasis granules. NIHSS score and TCM syndromes score were recorded once before-3-0 days and 28 卤3 days after medication, and statistical analysis was done to evaluate the clinical efficacy of Quphlegm Huayu granule. The result is 1: 1. Balanced comparison between the two groups: there was no significant difference in gender, age distribution between the two groups (P0.05), indicating comparability between the two groups, NIHSS score scores between the two groups before treatment, no significant difference (P0.05), indicating that there is comparability between the two groups; There was no significant difference between the two groups in TCM syndrome score before treatment (P0.05), indicating that there was comparability between the two groups. 2. Results: there was significant difference in NIHSS scores between the two groups after treatment (P0.05), indicating that the NIHSS score scores of the two groups were lower than those before treatment, and the NIHSS scores of the experimental group were compared with those of the control group after treatment. There was significant difference (P0.05), which showed that the experimental group was superior to the control group in the overall curative effect. The scores of TCM syndromes in the two groups after treatment were significantly different from those before self-treatment (P0.05), which indicated that the scores of TCM syndromes in the two groups were lower than those before treatment, and the scores of TCM syndromes in the experimental group and the control group after treatment were compared with those in the control group. There is a significant difference (P0.05), indicating that in the overall efficacy, the trial group is better than the control group. 3. Safety test: after safety test, observe the patient's blood routine, urine routine, stool routine, electrocardiogram, liver function, kidney function, blood rheology, whether there are any adverse events and adverse reactions during medication, The results showed that there was no adverse reaction during the treatment with Quphlegm Huayu granule, and there was no interruption of treatment because of serious adverse events. Conclusion: Quphan Huayu granule can improve the clinical symptoms of the patients with wind and phlegm stasis syndrome in convalescent period of apoplexy, the curative effect of Quphlegm Huayu granule is reliable, and there are no adverse reactions and adverse events during the treatment with Quphan Huayu granule.
【学位授予单位】：辽宁中医药大学
【学位级别】：硕士
【学位授予年份】：2017
【分类号】：R255.2

【参考文献】